Health-Related Quality of Life and Survival in Metastasized Non-Small Cell Lung Cancer Patients with and without a Targetable Driver Mutation
| Autor: | Corina van den Hurk, Annemarie Becker-Commissaris, Vashti N. M. F. Tromp, Iris Walraven, Nicole E Billingy |
|---|---|
| Přispěvatelé: | Pulmonary medicine, Clinical pharmacology and pharmacy, CCA - Cancer Treatment and quality of life, Ophthalmology, APH - Quality of Care, APH - Aging & Later Life |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Article Gee All institutes and research themes of the Radboud University Medical Center Quality of life Internal medicine medicine Lung cancer Generalized estimating equation Survival analysis RC254-282 non-small cell lung cancer Health related quality of life business.industry metastatic lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease humanities health-related quality of life Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] Observational study Non small cell business targetable driver mutation |
| Zdroj: | Cancers Volume 13 Issue 17 Cancers, 13(17):4282. Multidisciplinary Digital Publishing Institute (MDPI) Cancers, 13, 17 Billingy, N E, Tromp, V N M F, van den Hurk, C J G, Becker-Commissaris, A & Walraven, I 2021, ' Health-Related Quality of Life and Survival in Metastasized Non-Small Cell Lung Cancer Patients with and without a Targetable Driver Mutation ', Cancers, vol. 13, no. 17, 4282 . https://doi.org/10.3390/cancers13174282 Cancers, Vol 13, Iss 4282, p 4282 (2021) Cancers, 13 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers13174282 |
| Popis: | Background: The aim of this study is to compare long-term health-related quality of life (HRQOL) and survival in metastatic NSCLC patients with (M+) and without (M−) a targetable driver mutation. Methods: An observational study was performed within the prospective SYMPRO-lung study (NL7897). HRQOL questionnaires were completed at baseline, 15 weeks, and 6 months. Generalized estimating equations (GEE) were used to assess clinically significant declines in HRQOL (> 10 points) over time. Kaplan–Meier survival curves were plotted for both progression-free survival (PFS) and overall survival (OS). Results: 81 metastatic NSCLC patients were included (M+ patients 16 (20%)). M+ patients had a significantly better global HRQOL (mean difference 12.8, ES 0.61), physical functioning (mean difference 13.4, ES 0.63), and less appetite loss (mean difference 23.1, ES 0.73) at 15 weeks of follow-up compared to M− patients. Patients with a clinically relevant decline in HRQOL at 6 months of follow-up had a significantly shorter PFS (5 months vs. 12 months, p-value < 0.001) and OS (11 months vs. 16 months, p-value 0.002). Conclusions: M− NSCLC patients have less favorable HRQOL over time compared to M+ patients. Furthermore, clinically relevant HRQOL declines over time were significantly associated with worse survival. HRQOL can therefore play an important role in in shaping patients’ expectations of their prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|